Akiko Fujimura

Fukuoka, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Inhibition of PTPN3 Expressed in Activated Lymphocytes Enhances the Antitumor Effects of Anti-PD-1 Therapy in Head and Neck Cancer, Especially in Hypoxic Environments.

Inhibition of PTPN3 Expressed in Activated Lymphocytes Enhances the Antitumor Effects of Anti-PD-1 Therapy in Head and Neck Cancer, Especially in Hypoxic Environments.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: July 31, 2023

Lacrimal Sac Tumors: A Single-institution Experience, Including New Insights.

Lacrimal Sac Tumors: A Single-institution Experience, Including New Insights.

Journal: In vivo (Athens, Greece)

Published: January 31, 2023

PTPN3 Could Βe a Therapeutic Target of Pancreatic Cancer.

PTPN3 Could Βe a Therapeutic Target of Pancreatic Cancer.

Journal: Anticancer research

Published: April 20, 2022

Corrigendum to "PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor" [Volume 14, Issue 9, September 2021, 101152].

Corrigendum to "PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor" [Volume 14, Issue 9, September 2021, 101152].

Journal: Translational oncology

Published: January 18, 2022

Cancer therapy that targets the Hedgehog signaling pathway considering the cancer microenvironment (Review).

Cancer therapy that targets the Hedgehog signaling pathway considering the cancer microenvironment (Review).

Journal: Oncology reports

Published: January 05, 2022

Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma.

Contribution of pre-existing neoantigen-specific T cells to a durable complete response after tumor-pulsed dendritic cell vaccine plus nivolumab therapy in a patient with metastatic salivary duct carcinoma.

Journal: Immunological investigations

Published: September 06, 2021

TrkB/BDNF Signaling Could Be a New Therapeutic Target for Pancreatic Cancer.

TrkB/BDNF Signaling Could Be a New Therapeutic Target for Pancreatic Cancer.

Journal: Anticancer research

Published: May 22, 2021

PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor.

PTPN3 is a potential target for a new cancer immunotherapy that has a dual effect of T cell activation and direct cancer inhibition in lung neuroendocrine tumor.

Journal: Translational oncology

Published: April 29, 2021

GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer.

GLI2 but not GLI1/GLI3 plays a central role in the induction of malignant phenotype of gallbladder cancer.

Journal: Oncology reports

Published: August 10, 2020

NFκB and TGFβ contribute to the expression of PTPN3 in activated human lymphocytes.

NFκB and TGFβ contribute to the expression of PTPN3 in activated human lymphocytes.

Journal: Cellular immunology

Published: June 05, 2020

Establishment and characterization of a primary cell culture derived from external auditory canal squamous cell carcinoma.

Establishment and characterization of a primary cell culture derived from external auditory canal squamous cell carcinoma.

Journal: FEBS open bio

Published: April 05, 2020

Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy.

Patched 1-interacting Peptide Represses Fibrosis in Pancreatic Cancer to Augment the Effectiveness of Immunotherapy.

Journal: Journal of immunotherapy (Hagerstown, Md. : 1997)

Published: December 14, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026